AlphaCentric Advisors LLC Raises Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

AlphaCentric Advisors LLC grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 23.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 47,500 shares of the biopharmaceutical company’s stock after purchasing an additional 9,000 shares during the quarter. Celldex Therapeutics makes up 1.3% of AlphaCentric Advisors LLC’s portfolio, making the stock its 19th biggest position. AlphaCentric Advisors LLC’s holdings in Celldex Therapeutics were worth $1,758,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CLDX. Values First Advisors Inc. increased its position in Celldex Therapeutics by 8.3% during the 2nd quarter. Values First Advisors Inc. now owns 21,319 shares of the biopharmaceutical company’s stock valued at $789,000 after buying an additional 1,627 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Celldex Therapeutics by 53.0% in the second quarter. Assenagon Asset Management S.A. now owns 139,162 shares of the biopharmaceutical company’s stock valued at $5,150,000 after purchasing an additional 48,231 shares during the period. Mirador Capital Partners LP increased its holdings in shares of Celldex Therapeutics by 7.3% in the second quarter. Mirador Capital Partners LP now owns 112,379 shares of the biopharmaceutical company’s stock valued at $4,159,000 after purchasing an additional 7,620 shares during the period. DNB Asset Management AS increased its holdings in shares of Celldex Therapeutics by 47.2% in the second quarter. DNB Asset Management AS now owns 7,872 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 2,523 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Celldex Therapeutics in the first quarter valued at about $824,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Tuesday, July 30th. Wolfe Research began coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $51.00 target price for the company. Finally, Wells Fargo & Company raised their price target on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.83.

Insider Buying and Selling at Celldex Therapeutics

In related news, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Celldex Therapeutics news, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Richard M. Wright sold 46,844 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $33.72, for a total value of $1,579,579.68. Following the sale, the vice president now directly owns 20,833 shares in the company, valued at approximately $702,488.76. The disclosure for this sale can be found here. Insiders have sold 266,332 shares of company stock valued at $9,155,821 over the last three months. 3.80% of the stock is owned by company insiders.

Celldex Therapeutics Trading Up 1.4 %

Shares of NASDAQ:CLDX traded up $0.53 during trading on Monday, hitting $37.70. 426,266 shares of the stock were exchanged, compared to its average volume of 777,705. The company has a fifty day moving average price of $36.53 and a two-hundred day moving average price of $38.72. The company has a market cap of $2.48 billion, a PE ratio of -13.04 and a beta of 1.58. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.05. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. Equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.